Decoy Therapeutics Provides Third Quarter 2026 Business Update
Decoy Therapeutics reports Q3 2026 progress, including an optimized pan-coronavirus lead with once-weekly dosing potential and $8.1 million in cash.
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.